Parkin controls dopamine utilization in human midbrain dopaminergic neurons derived from induced pluripotent stem cells
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
Parkinson's disease (PD) is defined by the degeneration of nigral dopaminergic (DA) neurons and can be caused by monogenic mutations of genes such as parkin. The lack of phenotype in parkin knockout mice suggests that human nigral DA neurons have unique vulnerabilities. Here we generate induced pluripotent stem cells from normal subjects and PD patients with parkin mutations. We demonstrate that loss of parkin in human midbrain DA neurons greatly increases the transcription of monoamine oxidases and oxidative stress, significantly reduces DA uptake and increases spontaneous DA release. Lentiviral expression of parkin, but not its PD-linked mutant, rescues these phenotypes. The results suggest that parkin controls dopamine utilization in human midbrain DA neurons by enhancing the precision of DA neurotransmission and suppressing dopamine oxidation. Thus, the study provides novel targets and a physiologically relevant screening platform for disease-modifying therapies of PD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“PD patient iPSC-derived dopaminergic neurons harboring Parkin mutation displayed decreased microtubule stability, increased oxidative stress, reduced dopamine uptake, and increased spontaneous dopamine release [36,37].”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [36]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors
Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., & Yamanaka, S. (2007) · Cell · doi:10.1016/j.cell.2007.11.019 · Cited by 20,221
Induced Pluripotent Stem Cell Lines Derived from Human Somatic Cells
Yu, J., Vodyanik, M. A., Smuga-Otto, K., Antosiewicz-Bourget, J., Frane, J. L., Tian, S., Nie, J., Jonsdottir, G. A., Ruotti, V., Stewart, R., et al. (2007) · Science · doi:10.1126/science.1151526 · Cited by 10,310
Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism
Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, M., Mizuno, Y., & Shimizu, N. (1998) · Nature · doi:10.1038/33416 · Cited by 5,227 · cited 1×
“In sharp contrast to the situation seen in PD patients with parkin mutation”
ResultParkin is recruited selectively to impaired mitochondria and promotes their autophagy
Narendra, D., Tanaka, A., Suen, D.-F., & Youle, R. J. (2008) · The Journal of Cell Biology · doi:10.1083/jcb.200809125 · Cited by 4,026 · cited 1×
“Parkin mutations did not significantly affect mitochondria We examined whether the loss of parkin significantly affect mitochondria by treating the four lines of iPSC-derived neurons without or with CCCP (10 μM for 16 h) to induce mitophag”
BackgroundHighly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling
Chambers, S. M., Fasano, C. A., Papapetrou, E. P., Tomishima, M., Sadelain, M., & Studer, L. (2009) · Nature Biotechnology · doi:10.1038/nbt.1529 · Cited by 3,620
Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase
Shimura, H., Hattori, N., Kubo, S.-I., Mizuno, Y., Asakawa, S., Minoshima, S., Shimizu, N., Iwai, K., Chiba, T., Tanaka, K., et al. (2000) · Nature Genetics · doi:10.1038/77060 · Cited by 2,024
Lang, A. E., & Lozano, A. M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810083391506 · Cited by 1,994
MONOAMINE OXIDASE: From Genes to Behavior
Shih, J. C., Chen, K., & Ridd, M. J. (1999) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.22.1.197 · Cited by 1,206 · cited 1×
“, which are mitochondrial enzymes responsible for the oxidative deamination of dopamine , a reaction that produces large quantities of reactive oxygen specie”
BackgroundHu, B.-Y., Weick, J. P., Yu, J., Ma, L.-X., Zhang, X.-Q., Thomson, J. A., & Zhang, S.-C. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0910012107 · Cited by 1,013
Oxidative stress and the pathogenesis of Parkinson's disease
Jenner, P., & Olanow, C. W. (1996) · Neurology · doi:10.1212/wnl.47.6_suppl_3.161s · Cited by 971
Research works printed but not linked: 1
- Chambers SM Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling Nat Biotechnol 27 275 280 2009 19252484 PMC2756723
Cited by
Induced pluripotent stem cell technology: a decade of progress.
Shi, Y., Inoue, H., Wu, J. C., & Yamanaka, S. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.245 · Cited by 1,525
Imaizumi, Y., Okada, Y., Akamatsu, W., Koike, M., Kuzumaki, N., Hayakawa, H., Nihira, T., Kobayashi, T., Ohyama, M., Sato, S., et al. (2012) · Molecular Brain · doi:10.1186/1756-6606-5-35 · Cited by 380
“Because increased levels of oxidative stress have been documented in other PD models [7,10,16,17], we examined oxidative metabolism in the iPSC clones by measuring the cellular levels of reduced glutathione (GSH).”
BackgroundInfluentialMonzio Compagnoni, G., Di Fonzo, A., Corti, S., Comi, G. P., Bresolin, N., & Masliah, E. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-01926-1 · Cited by 378
Mitochondrial Regulation in Pluripotent Stem Cells
Xu, X., Duan, S., Yi, F., Ocampo, A., Liu, G.-H., & Izpisua Belmonte, J. C. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.06.005 · Cited by 374
Induced Pluripotent Stem Cells and Their Use in Human Models of Disease and Development
Karagiannis, P., Takahashi, K., Saito, M., Yoshida, Y., Okita, K., Watanabe, A., Inoue, H., Yamashita, J. K., Todani, M., Nakagawa, M., et al. (2019) · Physiological Reviews · doi:10.1152/physrev.00039.2017 · Cited by 368
Synaptic, Mitochondrial, and Lysosomal Dysfunction in Parkinson’s Disease
Nguyen, M., Wong, Y. C., Ysselstein, D., Severino, A., & Krainc, D. (2019) · Trends in Neurosciences · doi:10.1016/j.tins.2018.11.001 · Cited by 323
“Interestingly, dopaminergic neurons derived from parkin patients demonstrate increased intracellular DA, suggesting that DA packaging or metabolism in parkin-mutant neurons may be impaired [60].”
BackgroundModeling ALS with iPSCs reveals that mutant SOD1 misregulates neurofilament balance in motor neurons
Chen, H., Qian, K., Du, Z., Cao, J., Petersen, A., Liu, H., Blackbourn, L. W., Huang, C.-L., Errigo, A., Yin, Y., et al. (2014) · Cell stem cell · doi:10.1016/j.stem.2014.02.004 · Cited by 318
“Nevertheless, some pathologic phenotypes seem to appear in ‘‘young’’ neural cells that are differentiated from patient iPSCs, including ALS, Alzheimer’s disease, and Parkinson’s disease (Israel et al., 2012; Jiang et al., 2012; Serio et al., 2013).”
Mitochondrial quality control in health and in Parkinson’s disease
Eldeeb, M. A., Thomas, R. A., Ragheb, M. A., Fallahi, A., & Fon, E. A. (2022) · Physiological Reviews · doi:10.1152/physrev.00041.2021 · Cited by 265
Investigating human disease using stem cell models
Sterneckert, J. L., Reinhardt, P., & Schöler, H. R. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3764 · Cited by 249
Aflaki, E., Borger, D. K., Moaven, N., Stubblefield, B. K., Rogers, S. A., Patnaik, S., Schoenen, F. J., Westbroek, W., Zheng, W., Sullivan, P., et al. (2016) · Journal of Neuroscience · doi:10.1523/jneurosci.0636-16.2016 · Cited by 227
“It has been shown that dopaminergic neurons with mutant Parkin exhibit increased transcription of monoamine oxidases, increased DA release, and reduced DA uptake (Jiang et al., 2012).”
BackgroundWoodard, C. M., Campos, B. A., Kuo, S.-H., Nirenberg, M. J., Nestor, M. W., Zimmer, M., Mosharov, E. V., Sulzer, D., Zhou, H., Paull, D., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.10.023 · Cited by 222
“Dopaminergic neurons from genetic PD cases have been used to recapitulate relevant disease pathology, including a-synuclein accumulation, impaired dopamine (DA) release, mitochondrial dysfunction, vulnerability to oxidative stress, and increased ERK phosphorylation (Cooper et al., 2012; Devine et al., 2011; Jiang et a…”
InfluentialImpaired dopamine release in Parkinson’s disease
Cramb, K. M. L., Beccano-Kelly, D., Cragg, S. J., & Wade-Martins, R. (2023) · Brain · doi:10.1093/brain/awad064 · Cited by 207
“Parkin KO iPSC-derived DANs Increased release n/a n/a Jiang et al.(63) Pink1 Pink1 KO mouse Decreased release None Not investigated Kitada et al.”
BackgroundChung, S. Y., Kishinevsky, S., Mazzulli, J. R., Graziotto, J., Mrejeru, A., Mosharov, E. V., Puspita, L., Valiulahi, P., Sulzer, D., Milner, T. A., et al. (2016) · Stem Cell Reports · doi:10.1016/j.stemcr.2016.08.012 · Cited by 205
“Interestingly, our results on the expression of a-synuclein in Parkin iPSC-derivedmDAneurons are distinct from those of a previous study (Jiang et al., 2012), which reported no differences between disease and wild-type lines, but coincident with findings of partially upregulated a-synuclein in a…”
ResultBrain monoamine oxidase B and A in human parkinsonian dopamine deficiency disorders
Tong, J., Rathitharan, G., Meyer, J. H., Furukawa, Y., Ang, L.-C., Boileau, I., Guttman, M., Hornykiewicz, O., & Kish, S. J. (2017) · Brain · doi:10.1093/brain/awx172 · Cited by 201
Mitochondrial dynamics in Parkinson's disease: a role for α-synuclein?
Pozo Devoto, V. M., & Falzone, T. L. (2017) · Disease Models & Mechanisms · doi:10.1242/dmm.026294 · Cited by 177
“, 2012; Su and Qi, 2013), Parkin (Jiang et al., 2012; Imaizumi et al., 2012) or PINK1 (Seibler et al.”
BackgroundRecent Advances in Methamphetamine Neurotoxicity Mechanisms and Its Molecular Pathophysiology
Yu, S., Zhu, L., Shen, Q., Bai, X., & Di, X. (2015) · Behavioural Neurology · doi:10.1155/2015/103969 · Cited by 175
Antioxidant gene therapy against neuronal cell death
Navarro-Yepes, J., Zavala-Flores, L., Anandhan, A., Wang, F., Skotak, M., Chandra, N., Li, M., Pappa, A., Martinez-Fong, D., Del Razo, L. M., et al. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.12.007 · Cited by 176
“Parkin deficiency induces mitochondrial dysfunction and oxidative stress (Palacino et al., 2004), as well as an increase in monoamine oxidase (MAO) expression (Jiang et al., 2012).”
Genetic predispositions of Parkinson’s disease revealed in patient-derived brain cells
Tran, J., Anastacio, H., & Bardy, C. (2020) · npj Parkinson's Disease · doi:10.1038/s41531-020-0110-8 · Cited by 176
Guided Self‐Propelled Leaping of Droplets on a Micro‐Anisotropic Superhydrophobic Surface
Liu, J., Guo, H., Zhang, B., Qiao, S., Shao, M., Zhang, X., Feng, X., Li, Q., Song, Y., Jiang, L., et al. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201600224 · Cited by 167
Goldstein, D. S., Kopin, I. J., & Sharabi, Y. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.06.006 · Cited by 165
“Hypofunctional parkin mutation would be expected to release MAO-A from inhibitory restraint and thereby promote DOPAL production.”
BackgroundInfluentialKouroupi, G., Taoufik, E., Vlachos, I. S., Tsioras, K., Antoniou, N., Papastefanaki, F., Chroni-Tzartou, D., Wrasidlo, W., Bohl, D., Stellas, D., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1617259114 · Cited by 150
Physiological Characterisation of Human iPS-Derived Dopaminergic Neurons
Hartfield, E. M., Yamasaki-Mann, M., Ribeiro Fernandes, H. J., Vowles, J., James, W. S., Cowley, S. A., & Wade-Martins, R. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087388 · Cited by 147
“In the light of critical role of Ca2+ signalling in Parkinson’s disease, we next recorded changes in spontaneous Ca2+ signals during neuronal maturation.”
BackgroundInfluentialPluripotent stem cell-based therapy for Parkinson’s disease: Current status and future prospects
Sonntag, K.-C., Song, B., Lee, N., Jung, J. H., Cha, Y., Leblanc, P., Neff, C., Kong, S. W., Carter, B. S., Schweitzer, J., et al. (2018) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2018.04.005 · Cited by 143
Aberrant epigenome in iPSC ‐derived dopaminergic neurons from Parkinson's disease patients
Fernández‐Santiago, R., Carballo‐Carbajal, I., Castellano, G., Torrent, R., Richaud, Y., Sánchez‐Danés, A., Vilarrasa‐Blasi, R., Sánchez‐Pla, A., Mosquera, J. L., Soriano, J., et al. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201505439 · Cited by 139
“…studies on iPSC-derived DAn did not explore in the role of the epigenome in PD (Byers et al, 2011; Nguyen et al, 2011; Seibler et al, 2011; Cooper et al, 2012; Jiang et al, 2012; Sanchez-Danes et al, 2012b; Rakovic et al, 2013; Reinhardt et al, 2013; Ryan et al, 2013; Schondorf et al, 2014).”
BackgroundResultStructure and Function of Parkin, PINK1, and DJ-1, the Three Musketeers of Neuroprotection
Trempe, J.-F., & Fon, E. A. (2013) · Frontiers in Neurology · doi:10.3389/fneur.2013.00038 · Cited by 133
Cell cycle and p53 gate the direct conversion of human fibroblasts to dopaminergic neurons
Jiang, H., Xu, Z., Zhong, P., Ren, Y., Liang, G., Schilling, H. A., Hu, Z., Zhang, Y., Wang, X., Chen, S., et al. (2015) · Nature Communications · doi:10.1038/ncomms10100 · Cited by 132
“When we performed cell cycle analysis on ANLmp-infected fibroblasts that were treated with Dox in this media for 24 hr, we found that bFGF in Neural Induction Media promoted cell cycle entry in the absence of serum (Fig.”
InfluentialShaltouki, A., Sivapatham, R., Pei, Y., Gerencser, A. A., Momčilović, O., Rao, M. S., & Zeng, X. (2015) · Stem Cell Reports · doi:10.1016/j.stemcr.2015.02.019 · Cited by 130
“Indeed, a recent iPSC-based study showed that PARK2 controlled dopamine utilization in iPSC-derived dopaminergic neurons (Jiang et al., 2012).”
BackgroundResultMiller, S., & Muqit, M. M. K. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2019.04.029 · Cited by 129
“Relatively modest morphological or functional changes in mitochondria have been observed in iPSC-derived neurons with PINK1 [72,93,99] or Parkin mutations [9,43,46,100] and analysis of mitophagy in these neuronal systems using either mt-Keima”
Logan, S., Arzua, T., Canfield, S. G., Seminary, E. R., Sison, S. L., Ebert, A. D., & Bai, X. (2019) · Comprehensive physiology · doi:10.1002/cphy.c180025 · Cited by 153
Dynamic control of the dopamine transporter in neurotransmission and homeostasis
Bu, M., Farrer, M. J., & Khoshbouei, H. (2021) · npj Parkinson s Disease · doi:10.1038/s41531-021-00161-2 · Cited by 122
Direct conversion of human fibroblasts to induced serotonergic neurons
Xu, Z., Jiang, H., Zhong, P., Yan, Z., Chen, S., & Feng, J. (2016) · Molecular Psychiatry · doi:10.1038/mp.2015.101 · Cited by 115
Kwak, T. H., Kang, J. H., Hali, S., Kim, J., Kim, K.-P., Park, C., Lee, J.-H., Ryu, H. K., Na, J. E., Jo, J., et al. (2020) · Stem Cells · doi:10.1002/stem.3163 · Cited by 108
Parkin mutations reduce the complexity of neuronal processes in iPSC-derived human neurons
Ren, Y., Jiang, H., Hu, Z., Fan, K., Wang, J., Janoschka, S., Wang, X., Ge, S., & Feng, J. (2015) · Stem Cells · doi:10.1002/stem.1854 · Cited by 109
Self-citationModeling human neurological disorders with induced pluripotent stem cells
Imaizumi, Y., & Okano, H. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.12625 · Cited by 109
“2013), Parkinson’s disease (PD) (Devine et al. 2011; Nguyen et al. 2011; Seibler et al. 2011; Cooper et al. 2012; Imaizumi et al. 2012; Jiang et al. 2012; Liu et al. 2012a; Rakovic et al. 2012; Sanchez-Danes et al. 2012; Reinhardt et al. 2013), amyotrophic lateral sclerosis (Dimos et al.”
BackgroundNeural stem cells in Parkinson’s disease: a role for neurogenesis defects in onset and progression
Grand, J. N. L., González-Cano, L., Pavlou, M. A. S., & Schwamborn, J. C. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1774-1 · Cited by 112
Dumitriu, A., Latourelle, J. C., Hadzi, T. C., Pankratz, N., Garza, D., Miller, J. P., Vance, J. M., Foroud, T., Beach, T. G., & Myers, R. H. (2012) · PLoS Genetics · doi:10.1371/journal.pgen.1002794 · Cited by 91
“have been linked to PD in several genetic studies [15,25,26,27,28], and the dopamine receptor signaling pathway has been implicated”
BackgroundExperimental models of Parkinson's disease: Challenges and Opportunities
Lal, R., Singh, A., watts, S., & Chopra, K. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176819 · Cited by 95
Therapeutic Translation of iPSCs for Treating Neurological Disease
Yu, D. X., Marchetto, M. C., & Gage, F. H. (2013) · Cell stem cell · doi:10.1016/j.stem.2013.05.018 · Cited by 94
Ubiquitination Increases Parkin Activity to Promote Autophagic α-Synuclein Clearance
Lonskaya, I., Desforges, N. M., Hebron, M. L., & Moussa, C. E.-H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0083914 · Cited by 86
“dopamine levels [42,61], independent of LB formation.”
RetractedCairns, D. M., Chwalek, K., Moore, Y. E., Kelley, M. R., Abbott, R. D., Moss, S., & Kaplan, D. L. (2016) · Stem Cell Reports · doi:10.1016/j.stemcr.2016.07.017 · Cited by 83
“However, these protocols are often very time consuming, require multiple complicated intermediate steps such as the formation of non-adherent embryoid bodies and neurospheres (Jiang et al., 2012), and result in a large variability in neuronal differentiation (Hu et al., 2010).”
BackgroundInteraction between Parkin and α-Synuclein in PARK2-Mediated Parkinson’s Disease
Madsen, D. A., Schmidt, S. I., Blaabjerg, M., & Meyer, M. (2021) · Cells · doi:10.3390/cells10020283 · Cited by 92
Yagi, T., Kosakai, A., Ito, D., Okada, Y., Akamatsu, W., Nihei, Y., Nabetani, A., Ishikawa, F., Arai, Y., Hirose, N., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0041572 · Cited by 82
“A new era in in vitro modeling of neurodegenerative diseases recently began when iPSC technology was used to recapitulate the phenotypes of several late-onset neurodegenerative diseases, such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), diseases in which clinical signs appear on or after presenium [3–8].”
BackgroundMultitasking guardian of mitochondrial quality: Parkin function and Parkinson’s disease
Kamienieva, I., Duszyński, J., & Szczepanowska, J. (2021) · Translational Neurodegeneration · doi:10.1186/s40035-020-00229-8 · Cited by 87
“Mitophagy appears to be unaffected [152].”
BackgroundMethamphetamine induced neurotoxic diseases, molecular mechanism, and current treatment strategies
Shrestha, P., Katila, N., Lee, S., Seo, J. H., Jeong, J., & Yook, S. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113591 · Cited by 101
Pramanik, S., Sulistio, Y. A., & Heese, K. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-0214-7 · Cited by 82
Transdifferentiation: a new promise for neurodegenerative diseases
Mollinari, C., Zhao, J., Lupacchini, L., Garaci, E., Merlo, D., & Pei, G. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0891-4 · Cited by 83
Wu, Y.-Y., Chiu, F.-L., Yeh, C.-S., & Kuo, H.-C. (2019) · Open Biology · doi:10.1098/rsob.180177 · Cited by 75
Naoi, M., Maruyama, W., & Shamoto‐Nagai, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911059 · Cited by 77
“In induced pluripotent stem cells (iPSCs)-derived DA neurons prepared from patients with triplicated SNCA gene, MAO-A expression increased [42], MAO-A, and MAO-B in Parkin mutation [43] and MAO-B in LRRK2 mutation [44].”
BackgroundParkinson's disease in a dish – Using stem cells as a molecular tool
Badger, J. L., Llana, O. C., Hartfield, E. M., & Wade‐Martins, R. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.08.035 · Cited by 87
Hu, Z., Li, H., Jiang, H., Ren, Y., Yu, X., Qiu, J., Stablewski, A. B., Zhang, B., Buck, M. J., & Feng, J. (2020) · Science Advances · doi:10.1126/sciadv.aaz0298 · Cited by 75
“PCR was performed to detect episomal plasmids in genomic DNA isolated from primed C005 human iPSC, which was generated using episomal plasmids ( 25 ) or lentiviral transgene expressing OCT4 in genomic DNA isolated primed N004 human iPSC, which was generated using DOX-inducible lentiviruses expressing OCT4, SOX2, KLF4,…”
InfluentialOlesen, M. A., Villavicencio-Tejo, F., & Quintanilla, R. A. (2022) · Translational Neurodegeneration · doi:10.1186/s40035-022-00308-y · Cited by 88
Suzuki, S., Akamatsu, W., Kisa, F., Sone, T., Ishikawa, K., Kuzumaki, N., Katayama, H., Miyawaki, A., Hattori, N., & Okano, H. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.12.188 · Cited by 78
Induced pluripotent stem cells: a tool for modeling Parkinson’s disease
Bose, A., Petsko, G. A., & Studer, L. (2022) · Trends in Neurosciences · doi:10.1016/j.tins.2022.05.001 · Cited by 76
iPSC technology to study human aging and aging-related disorders
Liu, G., Ding, Z., & Belmonte, J. C. I. (2012) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2012.08.014 · Cited by 77
“SNCA triplication Fibroblasts 55 Retrovirus; OSKC No Yes SNCA expression doubled [54 ] Parkin (DExon 3 or and 5) Fibroblasts – Lentivirus; OSKC No Yes Increased spontaneous DA release, decreased DA uptake and elevated ROS [58]”
BackgroundUtility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy
Nicholson, M. W., Ting, C.-Y., Chan, D. Z. H., Cheng, Y.-C., Lee, Y.-C., Hsu, C.-C., Huang, C.-Y., & Hsieh, P. C. H. (2022) · Cells · doi:10.3390/cells11111853 · Cited by 65
“PD patient iPSCderived dopaminergic neurons harboring Parkin mutation displayed decreased microtubule stability, increased oxidative stress, reduced dopamine uptake, and increased spontaneous dopamine release [36,37].”
BackgroundActivation mechanisms of the E3 ubiquitin ligase parkin
Panicker, N., Dawson, V. L., & Dawson, T. M. (2017) · Biochemical Journal · doi:10.1042/bcj20170476 · Cited by 65
Ahfeldt, T., Ordureau, A., Bell, C., Sarrafha, L., Sun, C., Piccinotti, S., Graß, T., Parfitt, G. M., Paulo, J. A., Yanagawa, F., et al. (2020) · Stem Cell Reports · doi:10.1016/j.stemcr.2019.12.005 · Cited by 65
“Thus, all isogenic lines differentiated into functional DNs with electrophysiological properties similar to those described previously (Jiang et al., 2012; Kriks et al., 2011).”
ResultTokarew, J. M., Kodsi, D. N. E., Lengacher, N. A., Fehr, T. K., Nguyen, A., Shutinoski, B., O’Nuallain, B., Jin, M., Khan, J. M., Ng, A. C., et al. (2021) · Acta Neuropathologica · doi:10.1007/s00401-021-02285-4 · Cited by 67
Using iPS Cells toward the Understanding of Parkinson’s Disease
Torrent, R., De Angelis Rigotti, F., Dell'Era, P., Memo, M., Raya, A., & Consiglio, A. (2015) · Journal of Clinical Medicine · doi:10.3390/jcm4040548 · Cited by 60
“Jiang and colleagues showed that iPSC from patients carrying mutations in PARK2 enhanced the transcription of monoamine oxidase, the spontaneous release of dopamine and significantly decreased dopamine uptake, increasing susceptibility to reactive oxygen species [35].”
BackgroundQiang, L., Fujita, R., & Abeliovich, A. (2013) · Neuron · doi:10.1016/j.neuron.2013.06.002 · Cited by 59
PARK2 Mutation Causes Metabolic Disturbances and Impaired Survival of Human iPSC-Derived Neurons
Bogetofte, H., Jensen, P., Ryding, M., Schmidt, S. I., Okarmus, J., Ritter, L., Worm, C. S., Hohnholt, M. C., Azevedo, C., Roybon, L., et al. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00297 · Cited by 66
Ugun‐Klusek, A., Theodosi, T. S., Fitzgerald, J. C., Burté, F., Ufer, C., Boocock, D. J., Yu‐Wai‐Man, P., Bedford, L., & Billett, E. E. (2018) · Redox Biology · doi:10.1016/j.redox.2018.10.003 · Cited by 61
Parallel On-Chip Analysis of Single Vesicle Neurotransmitter Release
Yakushenko, A., Kätelhön, E., & Wolfrum, B. L. (2013) · Analytical Chemistry · doi:10.1021/ac4006183 · Cited by 60
Modeling Brain Disorders Using Induced Pluripotent Stem Cells
Vadodaria, K. C., Jones, J. R., Linker, S. B., & Gage, F. H. (2019) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a035659 · Cited by 54
“Interestingly, PD pathology impacts neuronal morphology and neurite outgrowth, a common assay for in vitro disease modeling (Jiang et al. 2012; Flierl et al. 2014; Skibinski et al. 2014).”
BackgroundToxicity testing and drug screening using iPSC-derived hepatocytes, cardiomyocytes, and neural cells
Csöbönyeiová, M., Polák, Š., & Danišovič, L. (2016) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2015-0459 · Cited by 52
The synaptic function of parkin
Sassone, J., Serratto, G. M., Valtorta, F., Silani, V., Passafaro, M., & Ciammola, A. (2017) · Brain · doi:10.1093/brain/awx006 · Cited by 52
“Spontaneous dopamine release was higher in autosomal recessive juvenile parkinsonism than in control neurons (Jiang et al., 2012) and overexpression of wild-type parkin, but not its mutant T240R, reduced spontaneous dopamine release in autosomal recessive juvenile parkinsonism neurons, thus…”
BackgroundInduced pluripotent stem cell (iPSC)-derived dopaminergic models of Parkinson's disease
Beevers, J. E., Caffrey, T. M., & Wade‐Martins, R. (2013) · Biochemical Society Transactions · doi:10.1042/bst20130194 · Cited by 56
Therapeutic Application of Stem Cell Technology toward the Treatment of Parkinson’s Disease
Nishimura, K., & TAKAHASHI, J. C. (2013) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b12-00929 · Cited by 57
Parkin loss of function contributes to RTP801 elevation and neurodegeneration in Parkinson’s disease
Romaní-Aumedes, J., Canal, M., Martín‐Flores, N., Sun, X., Pérez-Fernández, V., Wewering, S., Fernández‐Santiago, R., Ezquerra, M., Pont‐Sunyer, C., Lafuente, A., et al. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.333 · Cited by 59
Hargus, G., Ehrlich, M., Hallmann, A.-L., & Kuhlmann, T. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1222-6 · Cited by 60
“In addition, iPS cells have been derived from PD patients with either a homozygous deletion of exon 3 [85], exons 2-4 [79], exons 6 and 7 [79] or with a compound heterozygous deletion of exons 3 and 5 of PARKIN [85].”
BackgroundInfluentialiPSCs: On the Road to Reprogramming Aging
Soria-Valles, C., & López-Otín, C. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.05.010 · Cited by 48
“Neurons derived from mutant PARK2–iPSCs also exhibit increased oxidative stress, altered morphology, defective mitochondrial homeostasis, and microtubule alterations associated with impaired dopamine release [60–62].”
BackgroundAccelerating progress in induced pluripotent stem cell research for neurological diseases
Ito, D., Okano, H., & Suzuki, N. (2012) · Annals of Neurology · doi:10.1002/ana.23596 · Cited by 58
Kim, J., Sachdev, P. S., & Sidhu, K. (2013) · Stem Cell Research · doi:10.1016/j.scr.2013.06.005 · Cited by 48
Human disease modeling with induced pluripotent stem cells
Trounson, A. O., Shepard, K. A., & DeWitt, N. D. (2012) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2012.07.004 · Cited by 56
“In another study, in two individuals with mutations in parkin that occur in recessively inherited Parkinson’s disease, iPSC derived midbrain dopaminergic (dA) neurons showed signs of significantly elevated oxidative stress induced by dopamine oxidation as a result of increased monamine oxidases A and B, increased dopa…”
BackgroundiPSC for modeling neurodegenerative disorders
Valadez-Barba, V., Cota-Coronado, A., Hernandez-Perez, O. R., Lugo-Fabres, P. H., Padilla‐Camberos, E., Díaz, N. F., & Diaz-Martinez, N. E. (2020) · Regenerative Therapy · doi:10.1016/j.reth.2020.11.006 · Cited by 52
“These observations suggest that Parkin is involved in controlling DA neurotransmission and suppressing DA oxidation in human midbrain dopaminergic neurons [54].”
BackgroundFunctions and characteristics of PINK1 and Parkin in cancer
Matsuda, S., Nakanishi, A., Minami, A., Wada, Y., & Kitagishi, Y. (2015) · Frontiers in bioscience · doi:10.2741/4321 · Cited by 52
Sison, S. L., Vermilyea, S., Emborg, M. E., & Ebert, A. D. (2018) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-018-0893-8 · Cited by 53
Sen, T., & Thummer, R. P. (2022) · Neurotoxicity Research · doi:10.1007/s12640-022-00564-w · Cited by 55
Protein clearance strategies for disease intervention
Hommen, F., Bilican, S., & Vílchez, D. (2021) · Journal of Neural Transmission · doi:10.1007/s00702-021-02431-y · Cited by 51
Barral, S., & Kurian, M. A. (2016) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2016.00078 · Cited by 44
“Specifically, PD patient iPSC-derived midbrain dopaminergic neurons (mDA) recapitulate some PD disease features, including α-synuclein (αSYN) accumulation, oxidative stress, defects in neural outgrowth and mitochondrial dysfunction (Byers et al., 2011; Jiang et al., 2012; Reinhardt et al., 2013).”
BackgroundLopes, F. M., Bristot, I. J., da Motta, L. L., Parsons, R. B., & Klamt, F. (2017) · NeuroMolecular Medicine · doi:10.1007/s12017-017-8454-x · Cited by 55
“…that this model is the gold-standard PD in vitro model, because not only does it replicate more accurately the dopaminergic neuron physiology, but also the potential for generating patientspecific cells (Seibler et al. 2011; Jiang et al. 2012; Sánchez-Danés et al. 2012; Pu et al. 2012).”
BackgroundInduced pluripotent stem cells for modeling neurological disorders
Russo, F. B., Cugola, F. R., Fernandes, I. R., Pignatari, G. C., & Beltrão-Braga, P. C. B. (2015) · World Journal of Transplantation · doi:10.5500/wjt.v5.i4.209 · Cited by 48
Bose, A., & Beal, M. F. (2018) · European Journal of Neuroscience · doi:10.1111/ejn.14264 · Cited by 47
“Mutations in PARK2 may increase the susceptibility of neurons to oxidative stress (Aboud et al., 2015; Jiang et al., 2012).”
BackgroundLiu, B., Traini, R., Killinger, B. A., Schneider, B. L., & Moszczyńska, A. (2013) · Experimental Neurology · doi:10.1016/j.expneurol.2013.01.001 · Cited by 43
Payne, N. L., Sylvain, A., O’Brien, C., Herszfeld, D., Sun, G., & Bernard, C. C. A. (2014) · New Biotechnology · doi:10.1016/j.nbt.2014.05.001 · Cited by 45
“PD PARK2 (deletions) Lentivirus 5 factors Dopaminergic neurons: Increased transcription of monoamine oxidases, increased dopamine release, decreased dopamine uptake and DAT binding sites [127]”
BackgroundModeling Parkinson’s Disease Using Patient-specific Induced Pluripotent Stem Cells
Li, H., Jiang, H., Zhang, B., & Feng, J. (2018) · Journal of Parkinson s Disease · doi:10.3233/jpd-181353 · Cited by 50
Materials for Neural Differentiation, Trans‐Differentiation, and Modeling of Neurological Disease
Gong, L., Cao, L., Shen, Z., Shao, L., Gao, S., Zhang, C., Lü, J., & Li, W. (2018) · Advanced Materials · doi:10.1002/adma.201705684 · Cited by 41
Marotta, N., Kim, S., & Krainc, D. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1703671 · Cited by 42
“Midbrain Organoid: G2019S Upregulation of TXNIP genes and a-syn accumulation Kim et al 2019 [46] Midbrain Organoid: G2019S Increased FOXA2 expression Smits et al 2019 [160] Pink1/PINK1 Exon 3,5 Deletion Exon 3 Deletion Increased spontaneous dopamine release Decreased dopamine uptake and DAT-binding Increased MAO trans…”
BackgroundUsing induced pluripotent stem cell neuronal models to study neurodegenerative diseases
Zhang, X., Hu, D., Shang, Y., & Qi, X. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2019.03.004 · Cited by 38
“Jiang et al showed that iPSC-derived DA neurons from patients with Parkin mutation had decreased DA uptake and increased spontaneous DA release, whereas lentiviral expression of Parkin, but not its PD-linked mutant, rescued these phenotypes [91].”
BackgroundiPS cells in the study of PD molecular pathogenesis
Cobb, M. M., Ravisankar, A., Skibinski, G., & Finkbeiner, S. M. (2017) · Cell and Tissue Research · doi:10.1007/s00441-017-2749-y · Cited by 37
“neurons (Jiang et al. 2012), although a subsequent study observed no difference in expression of these transcripts (Imaizumi et al.”
BackgroundResultInfluentialGiguère, N., Pacelli, C., Saumure, C., Bourque, M.-J., Matheoud, D., Levesque, D., Slack, R. S., Park, D. S., & Trudeau, L.-É. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra117.000499 · Cited by 37
“lower expression of DAT in surviving DA neurons, a downregulation reported previously when this mouse was first characterized (48) andmore recently in Parkinmutant humanmidbrain DA neurons derived from induced pluripotent stem cells (50).”
BackgroundChumarina, M., Russ, K., Azevedo, C., Heuer, A., Pihl, M., Collin, A., Frostner, E. Å., Elmér, E., Hyttel, P., Cappelletti, G., et al. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0863-7 · Cited by 43
“On the other hand, transcriptional upregulation of MAO-A and MAO-B have been reported in patients with PARK2 and GBA variants in iPSC-derived neurons-based studies [34, 76].”
BackgroundModelling Parkinson’s Disease: iPSCs towards Better Understanding of Human Pathology
Avazzadeh, S., Baena-Montes, J. M., Keighron, C. N., Sánchez, Y. F., & Quinlan, L. R. (2021) · Brain Sciences · doi:10.3390/brainsci11030373 · Cited by 40
Bogetofte, H., Jensen, P., Okarmus, J., Schmidt, S. I., Agger, M., Ryding, M., Nørregaard, P., Fenger, C., Zeng, X., Graakjær, J., et al. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104581 · Cited by 35
Sheta, R., Teixeira, M., Idi, W., Pierre, M., Jacquet, A. D. R., Émond, V., Zorca, C. E., Vanderperre, B., Durcan, T. M., Fon, E. A., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-22158-4 · Cited by 39
Parkinson Disease: Translating Insights from Molecular Mechanisms to Neuroprotection
Pirooznia, S. K., Rosenthal, L. S., Dawson, V. L., & Dawson, T. M. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000189 · Cited by 37
Borresen, J., & Lynch, S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0048498 · Cited by 40
“Recently, it has been reported that scientists were able to grow brain nerve cells affected by Parkinson’s disease using human skin cell samples [54].”
BackgroundGhaffari, L. T., Starr, A., Nelson, A. T., & Sattler, R. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00056 · Cited by 34
“…SNCA gene and in patients with mutations in leucine-rich repeat kinase 2 (LRRK2) (Devine et al., 2011; Nguyen et al., 2011) and, rarely, in patients with mutations in parkin (Imaizumi et al., 2012), but not in patients with a mutation in PTEN-induced putative kinase 1 (PINK1) (Jiang et al., 2012).”
BackgroundJęśko, H. M., Lenkiewicz, A. M., Wilkaniec, A., & Adamczyk, A. (2019) · Acta Neurobiologiae Experimentalis · doi:10.21307/ane-2019-026 · Cited by 37
“Loss of parkin, in turn, led to increased MAO expression and free radical stress in human midbrain DAergic neurons (Jiang et al., 2012) (Fig.”
BackgroundJayaramayya, K., Iyer, M., Venkatesan, D., Balasubramanian, V., Narayanasamy, A., Subramaniam, M. D., Cho, S., & Vellingiri, B. (2020) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2020.02.001 · Cited by 36
Metadata
- Authors
- Jiang, H., Ren, Y., Yuen, E. Y., Zhong, P., Ghaedi, M., Hu, Z., Azabdaftari, G., Nakaso, K., Yan, Z., & Feng, J.
- Affiliations
- University at Buffalo, State University of New York (US)
- Roswell Park Comprehensive Cancer Center (US)
- Tottori University (JP)
- Corresponding author
- Feng, Jian
- Venue
- Nature Communications
- Published
- 2012-02-07
- Volume
- 3
- Issue
- 1
- Pages
- 668-668
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC3498452
- OpenAlex
- W2010478595
- Cited by
- 254
- References
- 39
- Citations by year
- 2026: 5 · 2025: 8 · 2024: 12 · 2023: 10 · 2022: 19 · 2021: 20 · 2020: 16 · 2019: 26 · 2018: 24 · 2017: 16 · 2016: 24 · 2015: 17 · 2014: 18 · 2013: 24 · 2012: 15
- FWCI
- 15.43
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature Communications (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Michael J. Fox Foundation for Parkinson's Research
- Roswell Park Cancer Institute
- State University of New York
- New York State Stem Cell Science
- National Natural Science Foundation of China (30928006)
- National Institutes of Health (5rc2ns070276-02, NS070276)
- U.S. Public Health Service (C024406)
- National Institute of Mental Health (R25MH077823)
- National Institute on Drug Abuse (R01DA026947)
- National Institute of Neurological Disorders and Stroke (RC2-NS070276, NS061856, R01NS061856, NS071122, NS070276, R01NS071122)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Keywords
- Parkin, Parkinson's disease, dopaminergic neurons, midbrain, dopamine uptake, dopamine release, monoamine oxidase, oxidative stress, induced pluripotent stem cells, parkin mutations, ubiquitin ligase, disease-modifying therapy
- MeSH terms
- Animals, Binding Sites, Brain, Dopamine, Fibroblasts, Gene Expression Regulation, Humans, Mitochondria, Models, Biological, Monoamine Oxidase, Mutation, Neurons, Oxygen, Parkinson Disease, Phenotype, Skin, Time Factors, Oxidative Stress, Ubiquitin-Protein Ligases, Mice, Induced Pluripotent Stem Cells, Dopaminergic Neurons
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.